Takeda Announces Reorganization to Propel Continued Growth

Osaka, Japan, September, 16^th, 2014 – Takeda Pharmaceutical Company Limited (“Takeda”) today announced plans to redesign its global organizational structure to realize its goal of becoming a more agile, best-in-class pharmaceutical company with both a patient and customer focus. The planned organizational changes are designed to allow Takeda to sharpen its strategy, to respond with greater agility to evolving market needs and capitalize on growth opportunities across the globe. This new organizational structure places a patient and customer centric mindset as our top priority, while aiming to clearly define accountability and ownership, simplify our organization, and allow the Company to operate more efficiently and competitively.

The Company's new organizational structure will redefine all regional commercial divisions into five Regional Business Units and two Specialty Business Units. The five newly established Regional Business Units will be Japan Pharma, Emerging Markets, United States, Europe-Canada, and Japan Consumer Healthcare, while the two newly established Specialty Business Units will be Oncology and Vaccines. Additionally, the R&D organization will be realigned into four Therapeutic Area Units, namely Central Nervous System (CNS), Cardiovascular and Metabolic (CVM), Gastroenterology (GI) and Oncology.
*Please reference the following pages for further details regarding the redesigned organizational structure.

Christophe Weber, the President and Chief Operating Officer of Takeda, explained, “Our aspiration for Takeda is to be the best-in-class company in every aspect of our business. To accomplish this, we need greater proximity to the patients and our customers in order to truly understand their needs and respond appropriately. Takeda needs to establish clear accountabilities for a more efficient and agile organization that places the needs of patients and customers first. Only by continuing to challenge ourselves to change in this way can we ensure continued success in our R&D investments as well as the global healthcare market.”

The details and particulars of the transition plans are currently under consideration and will be further refined. However, it is planned that the changes announced today will be fully implemented by April 1^st.  
Further, all plans that may affect employees are provisional and subject to appropriate information and consultations processes with affected employees and their representatives to the extent required under applicable laws, as well as the subsequent final decision of the employing entity.

Takeda's Redesign of its Organizational Structure

I. Concept chart of the Redesigned Global Organization Structure

Please reference the attached "Appendix 1."

 

II. Key Features within the Redesigned Global Organizational Structure

1.        Establishment of 5 Regional Business Units

Five Business Units will be established: the Japan Pharma Business Unit, the US Business Unit, the EUCAN Business Unit (Europe and Canada), the Emerging Markets Business Unit, and the Japan Consumer Healthcare Business Unit.
Each Business Unit will promote business within their responsible countries and regions, strengthen essential functions, and firmly establish business operations with high degree of specialization that allows them to realize patient and customer centricity.

Key changes:

• In order to maintain the Number One position in Japan, the Japan Pharma Business Unit will be established by augmenting the current Pharmaceutical Marketing Division in Japan with strengthened, essential functions.
• The current North Asia commercial organization and Emerging Markets organization will be integrated to form the Emerging Markets Business Unit, headquartered in Singapore.

2.        Establishment of 2 Specialty Business Units

Two Specialty Business Units will be established for Oncology and Vaccines, in order to accelerate the globalization of specialty businesses.

Key changes:

• Creating Specialty Business Units devoted to these two therapeutic areas will allow Takeda to further improve the company's ability to respond to patients' and physicians' unique needs, as well as to effectively maximize the success of each business.

3.        Establishment of 4 Therapeutic Area Units

To further promote therapeutic area strategy as well as asset strategies, the operational structure of Takeda's R&D organization will be simplified to establish four Therapeutic Area Units (TAUs). In addition, Takeda will strengthen the collaboration between R&D and commercial organization in order to further incorporate the insights obtained from patients and customers into its R&D activities. 

Key changes:

The below organizations will be realigned and established as direct reports to the Chief Medical and Scientific Officer.

• The TAUs will be realigned into 4 areas: Central Nervous System (CNS), Cardiovascular and Metabolic (CVM), Gastroenterology (GI), and Oncology.

- Current research in the Immunology area will be integrated into the CNS TAU.

- Current research in the Respiratory area will be integrated into the CVM TAU.

• Global Medical Office and Global Development Operations will support the above four TAUs.

 

III. Takeda Executive Team:

Effective October 1^st, 2014, Takeda Executive Team (TET), consists of President Weber and his direct reports, is established. Please refer the Appendix 2 for more details about TET.

Introduction of Business Partner Model
In addition to the previously established and appointed positions of Chief Financial Officer (CFO), Global Human Resources Officer (GHRO), Chief Medical & Scientific Officer (CMSO), Global Manufacturing and Supply Officer (GMSO) and Global Quality Officer (GQO), Takeda will further recognize the following three newly established positions: Corporate Strategy Officer (CSO), Corporate Communications and Public Affairs Officer (CCPAO) and Global General Counsel (GGC).
The Business Partners, CSO, CFO, GHRO, GGC and CCPAO, will define the roles and accountabilities at the country, region, and global levels of the organizations for which they are responsible, with the goal of effectively supporting business throughout Takeda.

• Corporate Strategy Officer (CSO) will be accountable for Corporate Strategy Department, Global Business Development, Japan Consumer Healthcare Business Unit, and Global Commercial.
• Global General Counsel (GGC) will be accountable for Legal Department, Intellectual Property Department and Global Compliance.
• Corporate Communications and Public Affairs Officer (CCPAO) will be accountable for Corporate Communications Department, Corporate Social Responsibility (CSR), and Government Affairs.

Appendix 2

Appointment of Senior Leadership within the new Global Organizational Structure is as below;

※　The above appointments are effective October 1^st 2014

Anna Protopapas will step down as President of Millennium and Head of Global Licensing and Business Development and leave Takeda effective October 1, 2014. Anna has made significant contributions to Takeda’s globalization, including leading the strategic initiative that resulted in the acquisition of Nycomed, spearheading the early planning and implementation of Project Summit and leading the successful transition of Millennium into the Takeda family.

 

###

 

About Takeda Pharmaceutical Company Limited

Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for people worldwide through leading innovation in medicine. Additional information about Takeda is available through its corporate website, www.takeda.com.